Dis­co de­buts with €20M seed round to ad­vance sur­faceome-based plat­form, with sup­port from Ab­b­Vie

Dis­co Phar­ma­ceu­ti­cals has ar­rived with €20 mil­lion ($21.9 mil­lion) in its pock­ets and Big Phar­ma back­ing, with the Ger­man com­pa­ny aim­ing to ad­vance its sur­face pro­teomics tech­nol­o­gy to dis­cov­er new on­col­o­gy tar­gets.

The seed round was led by Sofinno­va Part­ners with sup­port from Ab­b­Vie Ven­tures, M Ven­tures and Panakès Part­ners. The pro­ceeds will be used to map can­cer cells us­ing Dis­co’s plat­form fo­cused on sur­faceomes, which refers to all sur­face pro­teins of a cell or or­gan­ism.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER